Fineline Cube

Follow:
14420 Articles
NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ
Company

NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ

Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Others

Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC
CompanyDrug

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

National Health Commission Unveils Fourth Drug List for Generic Development
Policy / Regulatory

National Health Commission Unveils Fourth Drug List for Generic Development

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition
Company

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth
Company

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment
CompanyDrug

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
CompanyLegal / IP

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China

BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing
CompanyDeals

BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea
CompanyDeals

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD
CompanyDeals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development
CompanyDeals

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development